ストックスクリーナーアプリを入手
2.82
8.05%
0.21
アフターアワーズ：
2.82
前日終値:
$2.61
開ける：
$2.81
24時間の取引高:
7.27M
Relative Volume:
1.49
時価総額：
$868.84M
収益：
$248.37M
当期純損益:
$11.74M
株価収益率:
56.40
EPS:
0.05
ネットキャッシュフロー:
$18.24M
1週間 パフォーマンス:
-4.41%
1か月 パフォーマンス:
-50.87%
6か月 パフォーマンス:
-47.97%
1年 パフォーマンス:
-46.29%
1日の値動き範囲:
$2.715
$2.92
1週間の範囲:
$2.5215
$2.97
52週間の値動き範囲:
$2.5215
$6.51
Mannkind Corp Stock (MNKD) Company Profile
Compare MNKD vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
2.82 | 804.14M | 248.37M | 11.74M | 18.24M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.38 | 126.81B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
774.66 | 81.62B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.09 | 45.97B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.43 | 42.76B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
298.91 | 33.88B | 5.36B | 287.73M | 924.18M | 2.5229 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-27 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-11-24 | 開始されました | Truist | Buy |
| 2025-11-13 | 開始されました | Leerink Partners | Outperform |
| 2025-10-20 | 開始されました | Wells Fargo | Overweight |
| 2025-10-10 | 開始されました | Leerink Partners | Outperform |
| 2025-07-16 | 再開されました | H.C. Wainwright | Buy |
| 2025-04-10 | 開始されました | Mizuho | Outperform |
| 2025-02-10 | 開始されました | Wedbush | Outperform |
| 2024-12-20 | 開始されました | Wells Fargo | Overweight |
| 2024-12-19 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-09-09 | 再開されました | Leerink Partners | Outperform |
| 2024-06-13 | 開始されました | Rodman & Renshaw | Buy |
| 2023-10-10 | 開始されました | Wedbush | Outperform |
| 2021-05-14 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2019-12-24 | 開始されました | Oppenheimer | Outperform |
| 2019-10-25 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-05-14 | 開始されました | BTIG Research | Buy |
| 2019-03-04 | 開始されました | SVB Leerink | Outperform |
| 2019-02-22 | 開始されました | SVB Leerink | Outperform |
| 2018-02-28 | ダウングレード | Maxim Group | Hold → Sell |
| 2017-11-01 | ダウングレード | Maxim Group | Buy → Hold |
| 2017-10-10 | 開始されました | H.C. Wainwright | Buy |
| 2017-10-06 | 繰り返されました | Maxim Group | Buy |
| 2017-08-11 | 開始されました | Maxim Group | Buy |
| 2016-05-10 | 繰り返されました | Piper Jaffray | Underweight |
| 2016-05-10 | 繰り返されました | RBC Capital Mkts | Underperform |
| 2016-01-06 | 繰り返されました | Piper Jaffray | Underweight |
| 2016-01-06 | 繰り返されました | RBC Capital Mkts | Underperform |
| 2015-11-04 | ダウングレード | RBC Capital Mkts | Outperform → Underperform |
| 2015-09-09 | ダウングレード | Piper Jaffray | Neutral → Underweight |
| 2015-08-03 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2015-05-11 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2015-05-11 | 繰り返されました | MLV & Co | Hold |
| 2015-04-16 | 繰り返されました | RBC Capital Mkts | Outperform |
すべてを表示
Mannkind Corp (MNKD) 最新ニュース
MannKind at Barclays Healthcare Conference: Strategic Growth and Innovation - Investing.com
MannKind at Leerink Global Healthcare: Expanding Horizons in Pharma - Investing.com
MannKind (NASDAQ:MNKD) CEO Buys $259,000.00 in Stock - MarketBeat
MannKind (NASDAQ:MNKD) Hits New 12-Month LowHere's Why - MarketBeat
MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026 - The Manila Times
MannKind presents Afrezza data at diabetes conference - Investing.com
How The MannKind (MNKD) Investment Story Is Shifting With New Risks And 2026 Catalysts - Yahoo Finance
Vanguard Group Inc. Has $94.68 Million Holdings in MannKind Corporation $MNKD - MarketBeat
MannKind settles $36.3M convertible notes with cash, shares By Investing.com - Investing.com Canada
MannKind Corp (MNKD) Q4 2025 Earnings Call Highlights: Record Re - GuruFocus
MannKind settles $36.3M convertible notes with cash, shares - Investing.com
MannKind Announces Settlement of Convertible Senior Notes - Yahoo Finance
Wedbush Lowers Price Target for MannKind (MNKD) While Maintainin - GuruFocus
MannKind (NASDAQ:MNKD) Price Target Lowered to $8.00 at Wedbush - MarketBeat
MannKind Corporation (MNKD) Outlines Expansion Plans and Revenue Targets - Finviz
MannKind CEO and CFO to speak at two Miami healthcare events - Stock Titan
MannKind (NASDAQ:MNKD) Sets New 1-Year LowHere's What Happened - MarketBeat
MannKind (NASDAQ: MNKD) CFO adds 5,000 shares via stock purchase plan - Stock Titan
MannKind (MNKD) director adds 12,000 shares via Market Price Stock Purchase Plan - Stock Titan
MannKind (MNKD) director reports vesting of 45,025 performance-based stock options - Stock Titan
MannKind (MNKD) CEO gains stock and option vesting on milestones - Stock Titan
MannKind (NASDAQ:MNKD) Stock Price Down 6.6% After Analyst Downgrade - MarketBeat
H.C. Wainwright cuts MannKind stock price target on Tyvaso outlook By Investing.com - Investing.com Canada
H.C. Wainwright cuts MannKind stock price target on Tyvaso outlook - Investing.com
RBC Capital downgrades MannKind stock rating on royalty concerns By Investing.com - Investing.com Canada
RBC Capital downgrades MannKind stock rating on royalty concerns - Investing.com
A Look At MannKind (MNKD) Valuation After New United Therapeutics Inhaler Raises Royalty Concerns - simplywall.st
MannKind Corporation (NASDAQ:MNKD) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
MannKind Corp. Hits New 52-Week Low at $2.94 Amid Declining Stock Performance - Markets Mojo
MannKind Corporation (MNKD): A Bull Case Theory - Finviz
MannKind (NASDAQ:MNKD) Stock Rating Lowered by Wall Street Zen - MarketBeat
Beyond the Balance Sheet: What SWOT Reveals About MannKind Corp (MNKD) - GuruFocus
MNKD Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
MNKD: RBC Capital Downgrades MannKind with Price Target Cut by 5 - GuruFocus
What's Going On With MannKind Stock Friday? - Benzinga
Wells Fargo Lowers MNKD Price Target to $7.00, Maintains Overwei - GuruFocus
MNKD: HC Wainwright & Co. Lowers Price Target to $8.00 | MNKD St - GuruFocus
Reassessing MannKind (MNKD) After Sharp Recent Share Price Declines - Yahoo Finance
Why MannKind Stock Tumbled on Thursday - Yahoo Finance
MannKind at Oppenheimer Conference: Strategic Insights for 2026 - Investing.com
Compared to Estimates, MannKind (MNKD) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
MannKind (MNKD) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
MannKind’s Stock Plummets as United Therapeutics Unveils Rival Product - StocksToTrade
Earnings call transcript: MannKind Q4 2025 results show mixed performance By Investing.com - Investing.com South Africa
Earnings call transcript: MannKind Q4 2025 results show mixed performance - Investing.com Nigeria
MannKind Q4 2025 presentation shows 46% revenue surge, key catalysts ahead By Investing.com - Investing.com South Africa
MannKind Q4 2025 presentation shows 46% revenue surge, key catalysts ahead - Investing.com
MannKind hits 52-week low on Q4 earnings miss (MNKD:NASDAQ) - Seeking Alpha
MannKind Corp reports results for the quarter ended December 31Earnings Summary - TradingView
MannKind Corp (NASDAQ:MNKD) Reports Q4 2025 Revenue Beat and Strategic Outlook for 2026 - ChartMill
Earnings Flash (MNKD) MannKind Corporation Reports Q4 Revenue $112.0M, vs. FactSet Est of $97.6M - marketscreener.com
Mannkind Corp (MNKD) 財務データ
収益
当期純利益
現金流量
EPS
1.57%
0.40%
大文字化:
|
ボリューム (24 時間):